Canadian clinical trial registry

Go to Health Care Provider version

Centres

Study Description

(Translated from summary in French available on u-link.eu for the same study)

Gliomas are the most common brain tumors in children. They are classified into two groups: low-grade gliomas common in younger people and high-grade malignant gliomas that affect older children or adolescents. Genetic studies of these tumors have made it possible to highlight specific mutations which open the opportunity to new therapeutic avenues when standard treatments have not been effective.

In this protocol a combination of two drugs is used:

• Dabrafenib blocks a cellular process necessary for cell proliferation (it is a BRAF inhibitor)
• Trametinib blocks another process necessary for cell proliferation (it is a MEK inhibitor)

This study explores the efficacy and tolerance of these two new medications taken together.

Their association is studied on the two groups of glioma as follows:

• For children with high-grade glioma who have not responded to the standard treatment, the two molecules are taken orally every day.
• For children with low-grade glioma, the children are divided into 2 groups by drawing lots (randomization):
  • The first group receives the two molecules orally every day.
  • The second group receives classical chemotherapy (vincristine and carboplatin) according to standard of care. If the disease progresses despite these treatments, patient will be able to receive the two molecules tested
• In all cases the tumour will need to have a marker called BRAF V600 for the child to be considered for this study

Inclusion Criteria

(Translated from summary in French available on u-link.eu for the same study)

• Child aged 1 to 18
• Low or high grade glioma to whom standard treatments have not produced a sufficient response or who have relapsed.
• In all cases the tumour will need to have a marker called BRAF V600 for the child to be considered for this study
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This study is to assess the effectiveness of a chemotherapy called azacitidine in addition to the standard chemotherapy in infants diagnosed with acute lymphoblastic leukemia with a certain mutation called KMT2A-rearrangement.

Enrolled patients will receive four courses of azacitidine during their treatment. The study also looks at the side effects associated with these medications.

Inclusion Criteria

• Children less than 1 year of age
• New diagnosis of acute lymphoblastic leukemia
• Presence of a change called "KMT2A-rearrangement" in the leukemia cells

Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

This study is to assess the effectiveness of two drugs (bortezomib and vorinostat) in addition to standard therapy, for the treatment of infants with a new diagnosis of acute lymphoblastic leukemia. 

The study also looks at the side effects associated with these medications.

Bortezomib is a drug called a "proteasome inhibitor" while vorinostat is a drug called an "HDAC inhibitor".

Inclusion Criteria

• Children younger than 365 days of age with a new diagnosis of acute lymphoblastic leukemia
• They cannot have had prior treatment with other chemotherapies (with exception of a few medications, with limited amount of doses given).
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

The reason for this study is to see if the study medication LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma (neuroblastoma that has come back or is not improving despite treatment). LY3295668 erbumine blocks a protein called Aurora kinase A. Aurora kinase A is thought to contribute to the aggressiveness of neuroblastoma cells. 

The medication will be given either alone or in combination with chemotherapy.

Inclusion Criteria

• Age between 2 and 21 years
• Neuroblastoma that has come back (relapse) or is not improving despite treatments (refractory)
• The child must be able to swallow capsules
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This is a study to evaluate the dose, safety, tolerability, antitumor activity and other pharmacologic characteristics of avelumab (an antibody that binds and blocks PDL-1 on tumour cells).

This study has two parts. Part 1 will find the recommended dose for avelumab therapy and evaluate its safety. Part 2 will further evaluate the efficacy of avelumab therapy.

Inclusion Criteria

• Age between 0 and 18
• Solid malignant tumors (including brain tumors) or lymphoma for which no standard therapy is available, or with confirmed progression, or refractory to standard therapy
• Availability of tumor sample collected prior to avelumab treatment for subjects in Phase 2
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

Go to Health Care Provider version

Centres

Study Description

This clinical trial studies whether adding an oral medication called lenvatinib to chemotherapy with ifosfamide/etoposide improves outcomes for patients with osteosarcoma that has come back (relapse). 

Lenvatinib blocks cell proteins and signals directed at blood vessels that help the cancer to survive.

Patients can be treated in two different arms: Arm A: chemotherapy + lenvatinib or  Arm B : chemotherapy. The participants will be divided by chance into those two separate groups through a computerised process. The treating team will NOT decide into which arm a given patient will be assigned. At this time, it is not known which treatment option is best.

Inclusion Criteria

• Age between 2 and 25 years
• Osteosarcoma that has come back (relapse) or is not improving despite treatments (refractory)
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This is a study of two medications taken by mouth, called lenvatinib and everolimus. Lenvatinib blocks cell proteins and signals directed at blood vessels that help the cancer to survive. Everolimus is a cancer medicine that interferes with the growth of cancer cells and slows their spread in the body. It is called an mTOR inhibitor.

The phase 1 of this study has been completed, and now the phase 2 is on-going to understand the anti-cancer activity of those two medications taken together in patients with Ewing sarcoma, rhabdomyosarcoma or high grade glioma that has come back (relapsed) or is refractory to treatment.

Inclusion Criteria

• Age from 2 years to 21 years
• Diagnosis of Ewing sarcoma, rhabdomyosarcoma or high grade glioma that has come back (relapsed) or is refractory to treatment
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This study looks to assess if additional intensive treatment for patients with medulloblastoma and other embryonal brain tumors improves outcomes without adding significant short or long-term side effects. 

Inclusion Criteria

Patients 10 years of age of less with a diagnosis of medulloblastoma or CNS embryonal tumors of the brain or spinal cord. Any stage of medulloblastoma or CNS embryonal tumor in children less than 6 years old are eligible, whereas only high risk patients from 6-10 years of age are eligible. 

Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.